Scholarlink

<p>Brain metastasis occurs in approximately 50% of patients with advanced HER2-positive breast cancer. Despite improved prognosis, survival remains limited. This study aims to investigate the clinicopathological characteristics of HER2-positive breast cancer brain metastasis (BCBM) patients and their prognostic associations, to identify personalized treatment strategies to enhance survival. This retrospective study included HER2-positive BCBM patients treated at three institutions: the Fifth Medical Center of the Chinese PLA General Hospital, Peking University First Hospital, and the First Affiliated Hospital of Xi’an Jiaotong University. Clinical, pathological, and treatment data were collected. A prognostic model was developed using recursive variable selection, starting with significant variables from univariate analysis and refining them through a recursive loop in multivariate Cox regression. The model stratified patients into three risk groups: low-risk (score 0–1), intermediate-risk (score 2–3), and high-risk (score 4–6), based on various independent prognostic factors. The median survival times for the low-, intermediate-, and high-risk groups were 30, 20, and 10 months, respectively (<i>P</i> &lt; 0.0001, HR<sub>1</sub> = 1.35, 95% CI: 0.94–1.94; HR<sub>2</sub> = 4.02, 95% CI: 2.4–6.73). The mean ROC curve AUC values for the 1-year, 2-year, and 3-year prognostic predictions were 0.69, 0.70, and 0.61, respectively. In the independent validation cohort of 75 patients, prognostic stratification into low-, intermediate-, and high-risk groups revealed significant differences in outcomes (73 months vs. 35 months vs. 9 months, <i>P</i> &lt; 0.001, HR<sub>1</sub> = 2.68, 95% CI: 1.30–5.52; HR<sub>2</sub> = 8.82, 95% CI: 3.89–19.97). The mean AUC value for the 1-year and 2-year prognostic predictions in the validation cohort was 0.94, whereas the mean AUC value for the 3-year prognostic prediction was 0.81. This study developed a prognostic stratification model for HER2-positive BCBM patients based on clinicopathological characteristics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development of a prognostic risk stratification model for HER2-positive breast cancer brain metastasis and its implications in guiding treatment decisions

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月2日

查看全文
  • Jiaxin Chen,
  • Yuan Sh,
  • Danfeng Dong,
  • Huicui Yan,
  • Huiqiang Zhang,
  • Zisheng Wu,
  • Jinmei Zhou,
  • Xuexue Wu,
  • Fei Chu,
  • Zefei Jiang,
  • Shanhu Li,
  • Jin Yang,
  • Ling Xu,
  • Tao Wang

摘要

Brain metastasis occurs in approximately 50% of patients with advanced HER2-positive breast cancer. Despite improved prognosis, survival remains limited. This study aims to investigate the clinicopathological characteristics of HER2-positive breast cancer brain metastasis (BCBM) patients and their prognostic associations, to identify personalized treatment strategies to enhance survival. This retrospective study included HER2-positive BCBM patients treated at three institutions: the Fifth Medical Center of the Chinese PLA General Hospital, Peking University First Hospital, and the First Affiliated Hospital of Xi’an Jiaotong University. Clinical, pathological, and treatment data were collected. A prognostic model was developed using recursive variable selection, starting with significant variables from univariate analysis and refining them through a recursive loop in multivariate Cox regression. The model stratified patients into three risk groups: low-risk (score 0–1), intermediate-risk (score 2–3), and high-risk (score 4–6), based on various independent prognostic factors. The median survival times for the low-, intermediate-, and high-risk groups were 30, 20, and 10 months, respectively (P < 0.0001, HR1 = 1.35, 95% CI: 0.94–1.94; HR2 = 4.02, 95% CI: 2.4–6.73). The mean ROC curve AUC values for the 1-year, 2-year, and 3-year prognostic predictions were 0.69, 0.70, and 0.61, respectively. In the independent validation cohort of 75 patients, prognostic stratification into low-, intermediate-, and high-risk groups revealed significant differences in outcomes (73 months vs. 35 months vs. 9 months, P < 0.001, HR1 = 2.68, 95% CI: 1.30–5.52; HR2 = 8.82, 95% CI: 3.89–19.97). The mean AUC value for the 1-year and 2-year prognostic predictions in the validation cohort was 0.94, whereas the mean AUC value for the 3-year prognostic prediction was 0.81. This study developed a prognostic stratification model for HER2-positive BCBM patients based on clinicopathological characteristics.